In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Rishi P. Singh, MD, overviews post hoc analyses supporting angiopoietin-2 inhibition for treating retinal diseases.
“Recently, we’ve had the approval of a bispecific molecule that affects both angiopoietin-2 and VEGF molecules,” Singh said. “This is the faricimab molecule. It is the first bispecific in ophthalmology, and it is leading to some interesting findings in regards to the imaging biomarkers that we are finding in patients and when we compare them to VEGF-A suppression alone.”